<sup>64</sup>Cu radiolabeled nanomaterials for positron emission tomography (PET) imaging

⁶⁴Cu radiolabeled nanomaterials for positron emission tomography (PET) imaging

PDF

Xueqian Chen, Wenchao Niu, Zhongying Du, Yong Zhang, Dongdong Su^*, Xueyun Gao^*

Chinese Chemical Letters | 2022, 33(7) : 3349 - 3360

Less

Chinese Chemical Letters | 2022, 33(7): 3349-3360

• Review •

⁶⁴Cu radiolabeled nanomaterials for positron emission tomography (PET) imaging

Full

Xueqian Chen, Wenchao Niu, Zhongying Du, Yong Zhang, Dongdong Su^*, Xueyun Gao^*

Affiliations

Department of Chemistry and Biology, Faculty of Environment and Life, Beijing University of Technology, Beijing 100124, China

Published: 2022-07-15 doi: 10.1016/j.cclet.2022.02.070

Outline

Abstract

Less

The prevalence of positron emission tomography (PET) imaging has advanced biomedical applications for its ultrahigh sensitivity, deep tissue penetration and quantitative visualization of diseases in vivo. ⁶⁴Cu with ideal half-life and decay characteristics has been designed as radioactive probes for disease diagnosis. The currently reported ⁶⁴Cu-labeled nanomaterials have the advantages of long circulation time in serum, good biocompatibility and mature preparation methods, and have been used in vivo PET imaging, biodistribution and pharmacokinetic monitoring, and imaging guided therapy. At the same time, suitable carrier characteristics and radiolabeling strategies are particularly important in the ⁶⁴Cu PET imaging process. In this review, we summarize different imaging probe designs and ⁶⁴Cu radiolabeling strategies, as well as their eventual applications in biomedicine. The potential challenges and prospects of ⁶⁴Cu labeled nanomaterials are also described, which provides broad prospects for radiolabeling strategies and further applications.

Key words

⁶⁴Cu / Positron emission tomography / Chelating agent-free / Radiolabeling strategies / Imaging guided therapy

Cite this Article

Xueqian Chen, Wenchao Niu, Zhongying Du, Yong Zhang, Dongdong Su, Xueyun Gao. ⁶⁴Cu radiolabeled nanomaterials for positron emission tomography (PET) imaging[J]. Chinese Chemical Letters, 2022 , 33 (7) : 3349 -3360 . DOI: 10.1016/j.cclet.2022.02.070

Full Text

Less

1 Introduction

Less

Cancer screening, early diagnosis and timely treatment are crucial aspects to reducing the risk of advanced tumors [1-3]. Medical imaging technologies including positron emission tomography (PET), computed tomography (CT), photoacoustic tomography (PTOMS) and magnetic resonance imaging (MRI) are widely used to visualize physiological and pathological processes in vivo. Each imaging technology has its own advantages and can obtain extensive disease information [4-6]. Among them, PET imaging is an important imaging technology in clinical diagnosis. It has the advantages of non-invasive, ultrahigh sensitivity, deep tissue penetration and quantitative visualization of diseases and biological processes in vivo, and the capacity to provide functional and metabolic information at the molecular level [7, 8]. Therefore, radioisotope-based PET probes with ideal imaging performance and easy preparation will significantly improve the accuracy of early cancer diagnosis, tumor staging and therapeutic evaluation.

Potential estimates of the use of radioisotopes in PET imaging are made by pertinently considering their half-lives and decay characteristics [9, 10]. Radioisotopes with short half-lives require rapid and high-yield radiosynthesis, which makes their applications in vivo more challenging and impedes their development as radioisotopes for PET imaging. At the same time, due to the radiological hazards, the use of radioisotopes with relatively long half-lives remains a concern [11, 12]. Therefore, it is necessary to select a radioisotope with relatively suitable half-life and an extremely simplified radiolabeling procedure for PET imaging. Cuprum-64 (⁶⁴Cu) synchronously emits β⁺ (0.653 MeV, 17.8%), β⁻ (0.579 MeV, 38.4%), electron capture and gamma rays, with t_1/2 = 12.7 h [13, 14]. These decay characteristics make it an excellent radioisotope, which has potential applications in the construction of radioactive imaging probes for clinical diagnosis and as a source of radiotherapy. Meanwhile, the half-life is not long enough to cause unnecessary radiation damage to the patient, improving the safety of in vivo application. However, due to its rapid liver metabolism, it will not form effective aggregations in the lesion. At the same time, ions may cause strong toxicity. Therefore, using free ⁶⁴Cu²⁺ ions as probe will not produce ideal imaging results [15]. The electronic layer structure of Cu²⁺ makes it easy to form relatively stable metal complexes with amines, imines and pyridine [16, 17]. Therefore, the use of polynitrogen ligands as chelating agents is the main strategy to stabilize Cu²⁺. At the same time, a series of ⁶⁴Cu imaging probes consisting of targeting moieties (small molecules, monoclonal antibodies, peptides or aptamers), linkers and chelating agents were developed for sensitive and specific disease diagnosis [18-22]. With the development of nanotechnology, nanomaterials with mature preparation methods and good biocompatibility have become a reliable strategy for in vivo imaging [23-25]. Through the effective combination of nanotechnology, targeting moieties and Cu²⁺ organic chelating agents, such as 1,4,8,11-tetraazacyclododecane-1,4,8,11-tetraacetic acid (TETA) and 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA), radiolabeled nanoprobes with high stability and long circulation time in serum can be successfully prepared, making it possible for the use of ⁶⁴Cu radiolabeled probes with controllable behavior in vivo for qualitative and quantitative PET imaging [26-29]. Nevertheless, despite extensive screening and optimization studies on the structure of the chelating agents, when applied to organisms, the chelating agent bound to ⁶⁴Cu remains susceptible to acidic environment and is easily replaced by other proteins in organisms to produce free ⁶⁴Cu [5, 26]. The false signal caused by free ⁶⁴Cu²⁺ is still inevitable, so the stability and diagnostic accuracy of the radiolabeled probe cannot be guaranteed.

To avoid the limitations of using macrocyclic chelators, some nanoparticles themselves or their ligands contain groups with strong chelating properties with Cu²⁺, such as phenolic hydroxyl, carboxyl or sulfhydryl groups, which simplify the assembly of different functional moieties and show excellent labeling stability by a chelator-free method [30-33]. In addition, thanks to the major advances in radiolabeling methods, the radiochemical doping of ⁶⁴Cu has become an important way to prepare stable and reliable ⁶⁴Cu PET imaging agents [10, 34]. In this type of method, radioisotopes are integrated into the particle structure of the nanomaterial, rather than simply being attached to its surface through a chelating agent [35]. Since ⁶⁴Cu is used as a reactant in the probe preparation process and participates in the overall preparation of the doped nanoprobes [36, 37], it is necessary to develop suitable methods that well match the half-life of ⁶⁴Cu. Currently, well-defined radiation-stabilized ⁶⁴Cu nanoparticles with good reproducibility can be prepared by one-pot method, chemical reduction, codeposition and coating methods [38-41]. Therefore, ⁶⁴Cu-doped nanoprobes have the stability of radiolabeling and the natural behavior of nanomaterials in vivo, which can be used for high fidelity, highly sensitive and quantitative PET imaging [42].

PET imaging of ⁶⁴Cu radiolabeled nanomaterials is a great potential and fast-developing branch of in vivo imaging, biodistribution and pharmacokinetic monitoring, and imaging-guided therapy. The ingenious construction of ⁶⁴Cu radiolabeled nanomaterials, through the rational design of nanocarriers and radiolabeling strategies, offers many possibilities for improving the accuracy of cancer diagnosis, which has great application potential in nuclear medicine imaging and further facilitate clinical transformation [10, 29, 34]. In this review, we introduced in detail the design strategies and synthetic methodologies of various ⁶⁴Cu radiolabeled nanoprobes, mainly the latest developments and applications of chelating agent-free ⁶⁴Cu radiolabeled nanomaterials, and predicted their development trends (Fig. 1). We believe that this review will provide a broad perspective for researchers in this field.

2 PET imaging of radioactive ⁶⁴Cu-labeled nanomaterials

Less

The use of radioactive ⁶⁴Cu as a nuclear tracer to investigate the effects of PET imaging in vivo requires appropriate radiolabeling strategies and matched nanocarriers. In recent years, nanomaterials have provided suitable carriers for ⁶⁴Cu due to their specific targeting, excellent loading capacity and easy functional modification [14, 43, 44]. At the same time, the stable radiolabeling strategy of ⁶⁴Cu is another important factor that must be considered. Currently, there are two main strategies: chelating agent-based or chelating agent-free radiolabeling [10]. Combining nanocarriers and radiolabeling strategies, we mainly introduce Cu and Cu-doped metal clusters or nanoparticles, as well as nanoparticles or liposomes containing Cu chelating agent-like agents (porphyrin or similar structures) and their ⁶⁴Cu PET imaging applications. Table 1 summarizes the design strategies and techniques used to prepare radiolabeled [⁶⁴Cu]Cu nanoparticles and their applications in-vivo imaging [35, 38-40, 42, 45-75].

2.1 PET imaging of [⁶⁴Cu]Cu clusters, ⁶⁴Cu-doped nanoparticles and ⁶⁴Cu-radiolabeled nanoparticles

2.1.1 [⁶⁴Cu]Cu clusters for PET imaging

Metal clusters have attracted worldwide attention due to their ultrasmall size, robust preparation and good biocompatibility. As an emerging functional material, metal clusters have great potential in the field of biomedicine [36]. The introduction of the radionuclide ⁶⁴Cu into Cu clusters can be used for sensitive and deep-penetrating PET imaging. In the preparation strategy of this type of radioactive imaging agent, the radionuclide ⁶⁴Cu can be directly incorporated into the core of the clusters without the need of an external chelating agent, thereby achieving stronger radiochemical stability [76, 77]. At the same time, its reduced preparation process makes it more straightforward and less time-consuming. Most importantly, by avoiding the use of chelating agent molecules that may affect behaviors in vivo, the integrity and stability of nanomaterials are greatly improved [26, 78]. In this section, we summarize the design strategies of ⁶⁴Cu labeled Cu clusters and their applications in tumor imaging (Fig. 2A).

In 2015, Gao et al. pioneered the design of radioactive Cu clusters ([⁶⁴Cu]Cu_NC@BSA) using bovine serum albumin (BSA) as a scaffold [38]. [⁶⁴Cu]Cu_NC@BSA adopts a hot-plus-cold precursor strategy, which does not require additional chelating agents, and greatly improves the stability of radiolabeling. By pre-coupling a luteinizing hormone releasing hormone (LHRH) peptide with BSA molecule, a lung cancer-targeted radioactive [⁶⁴Cu]Cu_NC@BSA-LHRH was prepared for PET imaging of orthotopic lung cancer. Half an hour after the tail vein injection, the orthotopic A549 tumor was clearly delineated (10% ID/g) at the left lung of model mice with very little background signal at right lung and other organs (Fig. 2B). The example shows the superiority of this radioactive Cu label in PET imaging applications.

In 2019, Liu et al. employed the clinically used chemokine receptor CXCR4 specific binding peptide FC131 (cyclo[2-Nal-Gly-d-Tyr-NMe-d-Orn-Arg]) as a ligand to prepare radioactive Cu clusters through an intrinsic radiolabeling strategy [45]. ⁶⁴Cu was directly integrated into Cu clusters to obtain the imaging agent ⁶⁴Cu-CuNCs-FC131 with high specific activity and excellent stability. The imaging experiments showed that in three triple negative breast cancer (TNBC) models, PET imaging required only a small dose of contrast agent to evaluate the application potential of Cu clusters (Fig. 2C). In addition, the use of a de-identified human TNBC organization to evaluate the CXCR4 binding ability of ⁶⁴Cu-CuNCs-FC131 emphasizes the potential of future clinical applications. In 2020, the same group employed focused ultrasound (FUS) to effectively open the blood-brain barrier (BBB), and then delivered ultrasmall, biodegradable and intrinsically radiolabeled CuNCs for PET imaging and quantification of BBB opening efficiency in the mouse diffuse intrinsic pontine glioma (DIPG) model [46]. Both PET imaging and quantitative analysis of mouse brain showed high signal intensity of brain tumors (2.73% ± 0.18% ID/g), which confirmed that FUS-mediated ⁶⁴Cu-CuNCs can accelerate in situ drug delivery after entering tumor in the future, making it a potential early diagnosis and therapy means for DIPG. The radiolabeled Cu clusters prepared by this chelating agent-free strategy provides an effective tool for PET imaging in the biomedical field and has great potential for successful clinical transformation in the future.

2.1.2 [⁶⁴Cu]CuS and [⁶⁴Cu]CuO nanoparticles for PET imaging

Cu clusters can achieve sensitive PET imaging of tumors, but they lack inherent therapeutic properties. Composite copper nanoparticles, such as CuS and CuO nanoparticles, not only possess inherent radiolabeled Cu elements, but also have effective drug-carrying capabilities and drug delivery functions [47, 79]. Among them, CuS nanoparticles with strong near-infrared (NIR) absorption characteristics are novel and promising photothermal coupling agents, and CuS-based nanomaterials have received widespread attention in the field of diagnosis and treatment [80, 81]. In this section, we summarize the advantages and design strategies of ⁶⁴Cu labeled CuS and CuO nanoparticles and their applications of tumor imaging and photothermal therapy (PTT) (Fig. 3A).

In 2010, Li et al. pioneered the design of chelating agent-free and PEG-coated [⁶⁴Cu]CuS NPs for PET imaging [47]. It has great radiolabel stability and favorable pharmacokinetic characteristics (7.6% ± 1.4% ID/g) in human U87 glioblastoma model. The PET/CT images in U87 tumor-bearing mice showed that the average tumor-to-muscle (T/M) ratio was 6.55:1 at 24 h. In addition, unlike Cu clusters, the strong NIR absorption of CuS NPs enables them to be used as efficient PTT agents for photothermal ablation (PTA) therapy. In 2015, Li et al. reported a novel multifunctional, PET-visible and polyvinylpyrrolidone-coated CuS nanodots ([⁶⁴Cu]CuS NDs) [48]. The ultrasmall size of 5.6 nm ensures the escape of nonspecific uptake in reticuloendoreticuloendothelial system (RES) organs, and fast renal clearance up to 95% of [⁶⁴Cu]CuS NDs within 24 h. The CuS NDs still have potential for improvement, such as the introduction of receptor-specific targeting parts, to achieve a wide range of clinical significance.

Subsequently, in view of the excellent performance of [⁶⁴Cu]CuS NPs in PET imaging and PTT, Pellegrino et al. reported active targeting and radiolabeled photothermal probe ⁶⁴Cu: CuS nanocrystals bearing biotin molecules, which makes it more easier for radiotracers to be transferred to clinical medicine [82]. Similarly, Chen et al. used ferritin as a biological template to design ⁶⁴CuS-Fn nanocages (NCs) through biomineralization for photoacoustic/PET bimodal imaging and PTT [49]. The tumor uptake of ⁶⁴CuS-Fn NCs in U87MG tumor-bearing mice reached maximum (~10% ID/g) at 8 h postinjection, and the tumor accumulation in PET imaging was consistent with the PA signal (Fig. 3B). The integration of PA and PET provides high sensitivity, spatial resolution and unique recommendations for PTT, and has broad prospects in clinically transformable cancer therapy.

In 2021, Liu et al. engineered the ultrasmall CuO nanoparticles ⁶⁴Cu-Cu@CuOx-ECL1i-Gem with extracellular loop 1 inverso (ECL1i)-modified and loaded gemcitabine via ⁶⁴Cu intrinsic radiolabeling for PET-guided drug delivery into the pancreatic ductal adenocarcinoma (PDAC) tumors [50]. ECL1i peptide with targeting specificity for chemokine receptor 2 improves tumor accumulation and unessential nonspecific retention. PET images of KPPC mice and KPC mice distinctly demonstrated increased retention of ⁶⁴Cu-Cu@CuOx-ECL1i at the tumor region (Fig. 3C). Quantitation showed that the tumor accumulation rates of ⁶⁴Cu-Cu@CuOx-ECL1i in KPPC and KPC model mice were 11.16% ± 1.22% ID/g and 5.47% ± 0.75% ID/g, respectively. In addition, the T/M ratio imaged in KPPC mice (17.03 ± 3.43) was 2 times higher than that of KPC mice (8.71 ± 1.94). Taking advantages of selectively and sensitivity of actively targeted PET imaging, CCR2-targeted therapy of Cu@CuOx-ECL1i-Gem has shown admirable therapeutic efficacy in a syngeneic xenograft mouse model, demonstrating a promising image-guided therapy.

2.1.3 ⁶⁴Cu-doped Au nanoparticles for PET imaging

Au nanoparticles with particle sizes less than 100 nanometers have the advantages of good stability, good biocompatibility and easy modification [83]. In biological applications, the size-dependent metabolic properties of Au nanoparticles have always been a hot research topic [23, 58]. In particular, PET imaging based on Au nanoparticles has ultrahigh sensitivity and in vivo quantitative ability of biological processes, making it an ideal choice for intuitive analysis of pharmacokinetics [5, 84]. This section summarizes the different techniques for radiolabeling of Cu-doped Au nanoparticles for pharmacokinetic analysis and in vivo PET imaging (Fig. 4).

The one-pot method can directly synthesize radiolabeled nanoparticles. ⁶⁴Cu is distributed in the lattice of the nanoparticles, which significantly improves the stability of the radiolabel, especially can avoid the change in the behaviors of the nanoparticles in vivo caused by the surface modification of chelating agents [35]. Liu's group first reported ⁶⁴Cu doped Au nanoparticles (⁶⁴CuAuNPs) with monodisperse distribution (27 ± 3.2 nm) by directly synthesizing radioactive nanoparticles [35]. ⁶⁴CuAuNPs enhanced vascular permeability and retention (EPR) effect in tumor tissues and had good biocompatibility. It was successfully applied in accurate and high-contrast PET/CT imaging in breast cancer mouse models (Fig. 4B). Since the EPR effect, ⁶⁴CuAuNPs were continuously accumulated within tumor region over time, and tumor uptake reached 16.8% ± 0.98% ID/g with a high T/M ratio at 48 h post injection. However, the accumulation of nanoparticles in the non-specific mononuclear phagocyte system (MPS) is a problem faced by relatively large nanoparticles in vivo, which may cause potential long-term toxicity and affect the contrast of in vivo imaging. To overcome the above-mentioned challenge, Liu's group subsequently reported the PEG stabilized and ⁶⁴Cu doped Au nanoclusters ⁶⁴CuAuNCs (2.5 ± 0.8 nm), using the similar radiolabel strategy to evaluate the in vivo behavior and the effect of PET imaging [42]. In addition to favorable stable radiolabeling, the prepared ⁶⁴CuAuNCs showed distinct in vivo performance compared to the larger particles: rapid systematic clearance involved higher renal and hepatobiliary clearance, low MPS accumulation and low non-specific retention. All of these advances demonstrate the great potential of such radiative nanoclusters in monitoring and detecting tumors in vivo. To expand the application of the prepared radioactive nanoclusters, ⁶⁴CuAuNCs were further used to quantify focused ultrasound combined with microbubble (FUSM)-mediated uptake of pons in DIPG based on PET imaging [51]. After disruption of the fully functional BBB of DIPG and administration of ⁶⁴CuAuNCs, the synergistic quantification by PET imaging and inductively coupled plasma-mass spectrometry (ICP-MS) showed the accuracy of this strategy and its potential for further application in DIPG therapeutic drug delivery. The radioactive nanoclusters were then used for monitoring the delivery of FUSM-mediated intranasal administration [52]. Due to their ultrasmall size, ⁶⁴Cu labeled Au clusters can largely escape the accumulation of MPS, thereby significantly reducing non-specific signal in PET imaging, which is an effective strategy to improve their practical potential.

In addition to passive targeting, active targeting strategies based on specific receptor proteins of cells and tissues of interest are very effective ideas for improving tumor detection [85, 86]. For the accurate diagnosis of breast cancer (BC) and its metastasis in the early stage, Liu's group prepared radiolabeled nanoclusters (⁶⁴CuAuNCs-AMD3100) targeting BC up-expressed chemokine receptor CXCR4 [53]. The ultrasmall size (1.7 ± 0.3 nm) of ⁶⁴CuAuNCs-AMD3100 provides favorable in vivo distribution and renal and fecal clearance within 2 days. Compared with ⁶⁴Cu labeled AMD3100 and non-targeted ⁶⁴CuAuNCs, the CXCR4 targeting probe shows excellent sensitivity in detecting overexpressed CXCR4 in xenograft tumor and early BC premetastatic lesions in the lung, which shows great potential in accurately diagnosis of tumor lesions to guide treatment. Based on a similar strategy (Fig. 4C). Liu's group recently reported radiolabeled nanoclusters (⁶⁴Cu-AuNCs-ECL1i), which was prepared through a one-step reaction with a atherosclerosis-related CCR2 peptide, which can accurately diagnose the initiation and progression of atherosclerosis [54]. The active targeting strategy offers a unique accumulation of radioactive probe molecules at the region of interest, which greatly improves the high SBR signal and accuracy of imaging.

Mild radiolabeling technique such as chemical reduction can be used to effectively radiolabel complicated and functionalized nanomaterials while maintaining their multifunctionality [39]. Chen's group reported ⁶⁴Cu doped Au nanorods [⁶⁴Cu]AuNR808 for tumor diagnosis and PTT [39]. ⁶⁴Cu can be directly radiolabeled on functionalized Au nanoparticles by chemical reduction without affecting other loaded functional groups. At the same time, the prepared radioactive nanoprobe can be directly applied, which reduces the complicated processing after radiolabeling. Large particle size and conjugated RGD endow it with long blood circulation and tumor targeting ability, which significantly improved the tumor accumulation of [⁶⁴Cu]AuNR808 compared with pre-blocking and non-targeting probe group (Fig. 4D). Compared with chelate-labeled nanomaterials, [⁶⁴Cu]AuNR808 has RGD targeting and higher radiochemical stability, which significantly improves the accuracy of localization and quantification in PET imaging in vivo. Subsequently, Chen's group used the same method to prepare ⁶⁴Cu doped Au nanoclusters ⁶⁴CuAuNCs, with spontaneous self-illuminating/PET dual-mode in vivo imaging in a U87MG glioblastoma tumor-bearing mice [55]. PET imaging results showed that significant tumor uptake (14.9% ID/g) was observed 18 h post injection. More importantly, the frequency of the blue region of Cerenkov radiation emitted by ⁶⁴Cu matches well with the innate absorption of the prepared ⁶⁴CuAuNCs. Even in the absence of external excitation, the strong NIR fluorescence caused by Cerenkov resonance energy transfer (CRET) can achieve highly sensitive fluorescence imaging in vivo. ⁶⁴CuAuNCs with self-illuminating/PET dual-mode and high tumor uptake show great potential in accurately diagnosing cancer. In general, the chemical reduction method for radiolabeling is highly efficient and mild, and can be used for the radiolabeling of probes that are sensitive to extreme conditions, especially complex multifunctional probes.

Surface coating is an alternative strategy for obtaining radioactive nanoparticles. Andresen's group reported an example of using this chelating agent-free radiolabeling method [41]. First, ⁶⁴Cu²⁺ nonspecifically binds to the surface of freshly prepared Au seeds, additional Au shell by reducing the additional HAuCl₄·4H₂O coats and astricts the ⁶⁴Cu within the particles to obtain ⁶⁴Cu embedded AuNP (20–30 nm), where the radiolabeling efficiency is 53% ± 6%. Using the chelating agent-free strategy, ⁶⁴Cu embedded AuNPs with different coatings were prepared, and the radioactive nanoparticles showed favorable radiostability. Plasma half-life and tumor accumulation results showed that PEG coated ⁶⁴Cu embedded AuNP with had the best pharmacokinetic characteristics, which plasma half-life is about 9 h, and the tumor uptake is 3.89% ± 0.1% ID/g 24 h post injection.

Codeposition with other cold metal ions can directly incorporated ⁶⁴Cu into crystal lattice of nanoparticles [56]. Xia's group reported a radiolabeled core-shell tripod structure of PdCu@Au that was coreduced by Na₂PdCl₄ and CuCl₂ [56]. ⁶⁴Cu is embedded in the crystal lattice and the Au coating improves the stability of the radiolabel. In addition, an additional TNBC-targeted d-Ala1-peptide T-amide combined to the radioactive tripods greatly improves the accuracy of PET imaging and image-guided PTT. After systematic photothermal treatment, an obvious reduction of tumor metabolic activity was monitored by ¹⁸F-labeled fluorodeoxyglucose PET/CT imaging. Based on the same strategy, Liu's group reported an easy preparation of ⁶⁴Cu doped Au nanocages by codeposition of HAuCl₄, CuCl₂ and ⁶⁴CuCl₂ on the basis of Au nanocage [40]. The intergration of ⁶⁴Cu into the lattice of Au nanocages was improved, and the radioactive doped nanocages showed good tumor accumulation after PEGylation, thus showing great potential in PET image-guided cancer therapy. The above examples using different strategies to achieve ⁶⁴Cu radiolabeling, optimized the radiostability of PET probes, and made advances in vivo PET imaging, biodistribution and pharmacokinetic monitoring, and imaging guided therapy.

2.1.4 ⁶⁴Cu-doped iron oxide nanoparticles for PET imaging

PET imaging can provide ultrahigh sensitivity and quantitative molecular images, but its relatively low spatial resolution and lack of anatomical details of lesions hinder the in-depth development of clinical research [26, 87]. Utilizing the advantages of ⁶⁴Cu PET imaging, it can synergistically work with other imaging modalities. Iron oxide nanoparticles (IONP) are effective T₂ contrast agents for MRI, providing high-resolution two-dimensional or three-dimensional morphological and functional images with good soft tissue contrast [88]. Compared with PET imaging alone, ⁶⁴Cu-doped iron oxide nanoparticles have significant advantages in multifunctional imaging applications.

Louie et al. synthesized ⁶⁴Cu-doped iron oxide nanoparticles (DIO/⁶⁴Cu) with dextran coating by microwave-assisted synthesis technology [89]. Due to the controllable time, this synthesis method can not only synthesize nanoparticles (DIO/⁶⁴Cu) of different sizes to obtain the best blood retention time, but also effectively shorten the synthesis time, thus reducing the radioactive loss. Nanoparticles are potential candidates for MRI/PET bimodal imaging in future. In 2018, Strand et al. developed a hybrid PET-MRI probe based on superparamagnetic iron oxide nanoparticles (SPIONs), which was labeled with ⁶⁴Cu through a chelating agent-free method [57]. SPIONs have the advantages of high labeling efficiency (97%) and excellent chemical stability (> 95% at 24 h). In a tiny lymph node (LN) (1.7–2.5 mm), PET imaging can not only clearly describe LNs, but also distinctly prove the existence of ⁶⁴Cu-SPIONs in the large intestine, suggesting the final elimination path of the probe. Combining the high sensitivity of PET and the high spatial resolution of MRI, the hybrid ⁶⁴Cu-SPIONs probe provides more comprehensive information of diseases, and provides sensitive indications and accurate anatomical location for sentinel lymph nodes (SLN) lesions.

2.1.5 ⁶⁴Cu-chelated metal (Au, Fe) nanoparticles for PET imaging

The combination of ⁶⁴Cu²⁺ organic chelating agents such as TETA or DOTA with high stability and long cycle nanomaterials to form radiolabeled nanoprobes has made it possible to use ⁶⁴Cu²⁺ labeled PET probes with controllable behavior in vivo for qualitative and quantitative applications [26-29]. In this section, we summarize recently reported ⁶⁴Cu²⁺ chelating agent-labeled Au and iron oxide nanoparticles and their applications of tumor imaging (Fig. 5 and 6).

Au nanocages have great potential in tumor therapy due to their high photothermal efficiency and strong drug delivery capacity, but the tumor accumulation and pharmacokinetics remain unclear [90, 91]. Xia's group prepared two nanocages of different sizes (30 nm and 55 nm), which was conjugated with DOTA-NHS-ester and radiolabeled with ⁶⁴Cu to obtain the radioactive nanocages (⁶⁴Cu-DOTA-PEG-AuNCs) [58]. Results showed that compared with the 55 nm nanocages, the 30 nm radiolabeled nanocages have significant improvements in biodistribution, including a longer blood retention time and obviously reduced uptake by the RES. More importantly, the 30 nm nanocages showed a very favorable tumor uptake (~8% ID/g), T/M ratio (~23-fold) and favorable intratumoral diffusion at 24 h post injection in EMT-6 breast cancer mouse model (Fig. 5B). Later, Liu's group prepared a ⁶⁴Cu radiolabeled Au nanocages (⁶⁴Cu-AuNCs-PEG-MSH) based on the similar strategy, except that the nanocages surface was modified with an additional α-melanocyte-stimulating hormone (α-MSH) peptide for targeting enhanced melanocortin 1 receptor upregulated B16/F10 melanoma in a mouse model [59]. A higher tumor accumulation was observed on the melanoma target probe, providing good imaging results (Fig. 5C). Xie et al. studied the biodistribution of intratumor injection of Au nanoshells (⁶⁴Cu-nanoshells) based on same strategy [60]. Reducing the accumulation in MPS system and improving the efficiency of target localization are the goals of studying biodistribution profiles and visualizing biological processes in vivo in future clinical applications.

In terms of excellent internal circulation and MRI imaging characteristics, many multifunctional water-soluble SPIONs are coated with different ligands and have been reported for targeted drug delivery and multimodal tumor imaging (Fig. 6A). To label the effective tracer ⁶⁴Cu, researchers have employed different chelating agents (DOTA, NOTA, BP and DTPA) to functionalize SPIONs for PET imaging [61-65, 92]. In 2010, Chen et al. designed a HSA coated IONP (HSA-IONPs) functionalized with ⁶⁴Cu-DOTA and Cy5.5 for in vivo PET/NIRF/MRI trimodality imaging in a subcutaneous U87MG tumor-bearing mice [62]. Multimodal integrated imaging found that particles have better tumor accumulation in the lesion (Fig. 6B). Chen et al. developed a PASP-coated IONPs conjugated with the targeted cRGD and ⁶⁴Cu-DOTA to further detect tumors with high accuracy and effectiveness [63]. In addition to tumor diagnosis, Gong et al. firstly reported that SPIONs labeled with ⁶⁴Cu and cRGD showed excellent uptake (5.6% ± 1.7% ID/g at 6 h post injection) and accumulation in tumors, and then functionalized them with a pH-sensitive hydrazone bond to achieve specific drug release in the tumor microenvironment (Fig. 6C) [65]. The high-resolution of MRI and the quantitative monitoring of ⁶⁴Cu PET can accurately monitor the anti-cancer effect of nanocarriers in vivo, so that PET/MRI imaging can guide tumor-targeted drug delivery and further realize cancer therapy. More interestingly, Sutcliffe et al. evaluated ⁶⁴Cu radiolabeled Fe₃O₄ nanocarriers to noninvasively track and quantify the accumulation of NPs in lettuce seedlings [92]. The SPIONs-based dual-mode imaging strategy in this section provides a promising platform for comprehensive analysis of biodistribution profiles and visualization of biological processes through cross-over analysis of MRI/PET imaging.

2.1.6 ⁶⁴Cu-radiolabeled carbon nanoparticles for PET imaging

Carbon nanoparticles possess remarkable physicochemical with different morphologies, their multivalent effect can enhance the binding affinity with targeting ligands, and the ultra-high surface area can effectively load multiple molecules, providing new opportunities for biomedical research [93-95]. Carbon nanoparticles can be used not only as nanocarriers for radionuclides and anticancer drugs, but also as agents for directly mediating the destruction of cancer cells for cancer therapy, becoming potential candidates for bioimaging and cancer therapy [96]. In this section, we briefly enumerate the design strategies of ⁶⁴Cu-labeled carbonaceous nanomaterials and their applications in tumor imaging.

In 2007, Dai et al. took the lead in designing ⁶⁴Cu radiolabeled PET imaging probes SWNT-PEG₅₄₀₀-RGD and SWNT-PEG₂₀₀₀-RGD using single-walled carbon nanotubes (SWNT) as nanocarriers [66]. The probes were mainly composed of an RGD peptide capable of recognizing integrin α_vβ₃, two different PEG coatings (PEG₅₄₀₀ and PEG₂₀₀₀) and a radiolabel (⁶⁴Cu-DOTA). The SWNT conjugates showed excellent radiostability and prominent uptake in the liver. Furthermore, the long PEG-coated probe SWNT-PEG₅₄₀₀-RGD exhibited relatively long blood circulation times and efficient tumor accumulation (15% ID/g) in glioblastoma U87MG tumor-bearing mice. Subsequently, various macrocyclic chelator-functionalized carbonaceous nanomaterials such as carbon nanotubes, carbon dots, nanographenes and fullerenes were developed for sensitive PET imaging [97-101].

Different from traditional chelator-based radiolabeling, Cai et al. innovatively designed a chelator-free radiolabeling of probe ⁶⁴Cu-RGO-PEG based on the interaction between Cu and the p electrons of reduced graphene oxide (RGO) by intrinsically radiolabeling nanographene with ⁶⁴Cu [67]. The probe showed excellent labeling efficiency compared to graphene oxide (GO) and higher in vivo radiostability compared to NOTA-conjugated RGO, allowing for more reliable biodistribution assessment and accurate PET imaging. In addition, Wilson et al. have developed a strategy for the preparation of PET/MRI probe ⁶⁴Cu@GNT based on carbon nanotube platform-loaded Gd³⁺ and ⁶⁴Cu²⁺without chelating ligands. ⁶⁴Cu@GNT exhibited rapid clearance and enhanced accumulation in the lungs [102].

2.2 Porphyrin and their derivatives functionalized nanoparticles for PET imaging

Porphyrin and their derivatives such as Chlorin e6 (Ce6) have emerged as multifunctional agents widely used in the field of biomedicine [103-105]. They can be used as efficient photosensitizers for photodynamic therapy (PDT) and as fluorophores for fluorescence imaging [106]. More importantly, it can also chelate ⁶⁴Cu²⁺ for PET imaging [69]. Gao's group prepared a PET/CT dual-mode liposome contrast agent for early and accurate detection of A549 orthotopic lung tumors (Fig. 7A) [68]. PET imaging offers high sensitivity and quantitative visualization, but the poor spatial resolution is a shortcoming [68]. High-resolution CT complementary to PET imaging can provide detailed anatomical information. Iodixanol was encapsulated by cholesterol, DSPE-PEG2000-NHS and partial lysophosphatidylcholine-modified Ce6 for CT imaging, and then the lung cancer-targeting aptamer GLT21.T was conjugated to the surface of the liposome. Then ⁶⁴Cu²⁺ was quickly and efficiently labeled into liposomes to obtain the final probe (⁶⁴Cu@LCI-apt). When ⁶⁴Cu@LCI-apt was applied for imaging of orthotopic lung tumors, through the combination of PET imaging and CT, tumor lesions with a size of 500 µm can be clearly observed in the left lung of mice. The powerful imaging capability of ⁶⁴Cu@LCI-apt provides a broad prospect for early and accurate detection and location of tumor lesions.

The integration of therapeutic and diagnostic agents into one theranostic probe overcomes the differences in the biodistribution and pharmacokinetic of different agents, and is of great importance to the development of precision medicine [107]. Based on the multifunctional Ce6, Cai's group reported a photodynamic therapy nanoprobe guided by dual-mode optical/PET imaging [69]. Ce6 (PEG-Ce6) modified with an amphiphilic polymer is assembled into nanomicelles, which were then chelated with ⁶⁴Cu²⁺ to produce theranostic nanoprobe. The 20 nm-sized nanoprobe allows the serum stability and high tumor uptake observed in dual-mode imaging, and achieves excellent therapeutic effects through a low power radiation. The combination of multiple therapeutic methods is an effective way to improve the therapeutic effect. Combining dual optical-PET imaging and chemophototherapy, Cai's group then prepared radiolabeled DOX-loaded liposomes (Dox-CuPoP) by encapsulating DOX in the cavity and embedding porphyrin−phospholipid into the bilayer for fluorescence imaging, PDT and ⁶⁴Cu²⁺ chelation (Fig. 7B) [72]. After treating the 4T1 orthotopic tumors with the nanoprobe, effective growth inhibition was observed. In addition, dual-mode imaging found that nanoprobes accumulated in metastatic lung lesions.

The activatable probe has received widespread attention due to its high selectivity and sensitivity, which is conductive to accurate diagnosis of pathological processes and significantly reduce the severe side effects of anticancer drugs [108, 109]. Liu et al. reported a theranostic probe that combines multimodal imaging and light-activated and hypoxia-mediated tumor therapy [70]. Using liposomes as a carrier, a hypoxia-activated hydrophilic prodrug, AQ4N is encapsulated into its aqueous cavity, and hexadecylamine-modified chlorin e6 (hCe6) acts as a photosensitizer and stabilizing chelating agent embedded into its hydrophobic bilayer, and then ⁶⁴Cu²⁺ is labeled by chelating with hCe6 for PET imaging. PET imaging, fluorescence and photoacoustic imaging provide detailed and comprehensive information, including the biodistribution, pharmacokinetics and tumor accumulation of the theranostic vehicle in vivo, providing reliable evidence for subsequent treatment. When the tumor region is pertinently irradiated by 660 nm light, photodynamics therapy will be turned on, and at the same time, severe tumor hypoxia will appear in the tumor tissue, and AQ4N will be activated for chemotherapy. The obvious therapeutic effect and the accuracy of image-guided treatment show the great potential of theranostic probe in precision medicine. Chen's group prepared a glutathione-responsive multifunctional nanoprobe, a chemotherapeutic camptothecin as a prodrug for tumor chemotherapy, and a photosensitizer 2-(1-hexyloxyethyl)−2-devinyl pyropheophorbide-α (HPPH) for photodynamic therapy is conjugated by a disulfide linker (Fig. 8A) [73]. After ⁶⁴Cu²⁺ is chelated into HPPH, the radiolabeled dimer and degradable PEG-b-PLA are assembled into nanoparticles. The dimer is efficiently loaded into the nanoparticles. Under the guidance of quantitative PET imaging, the delivery efficiency of the prodrug dimer is greatly improved, and the GSH responsive linker shows high selectivity to tumor tissues, thereby obviously maintaining effective cytotoxicity to tumor tissues and reducing side effects to normal tissues. Due to its versatility, other Ce6-like structures can also be applied to ⁶⁴Cu²⁺ labeling biodistribution study and imaging-guide therapy in other tumor models [71, 74]. The effective and selective drug delivery of nanomaterials with PET imaging capability can significantly advance the intuitive analysis of pharmacokinetics and imaging-guide therapy, providing broad prospects in future cancer therapy.

⁶⁴Cu labeled nanomaterials can also be used to detect the effect of tumor immunotherapy. Gao's group reported a pyropheophorbide-A conjected PEG500 (PPa-PEGm) coated 5-fluorescein isothiocyanate modified tumor Trip2 antigen (FITC-Trip2) stabilized colloidal nanoparticles (Trp2/PPa-PEGm NPs) for tumor immunotherapy based on tumor vaccination (Fig. 8B) [75]. ⁶⁴Cu²⁺ was chelated to the tetrapyrrole ring of PPa for PET imaging. The short chain of PEG leads to a relatively small particle size, which is beneficial to the endocytosis of dendritic cells, then presents the antigen and triggers the antitumor effect of cytotoxic T-cell lymphocytes. After the administration of Trp2/⁶⁴Cu@PPa-PEGm NPs, the homing of dendritic cells to draining lymph nodes in vivo can be clearly observed by high sensitive PET imaging. In addition, the inoculated mice showed enhanced tumorous infiltration of CD8⁺ T cells and anti-tumor immune response, showing great potential as a multifunctional platform for ultra-high sensitive imaging-tracked tumor immunotherapy.

2.3 ⁶⁴Cu-functionalized liposomes for PET imaging

Liposomes can achieve long-circulation pharmacokinetics and non-specific deposition and retention of tumor sites [72, 110]. In addition, liposomes with satisfactory surface modification and strong loading capacity have been widely used as in vivo imaging and drug delivery systems [111]. ⁶⁴Cu radiolabeled liposomes are mainly divided into chelating agent-based surface labeling and chelating agents encapsulated in liposomes by ionophore-based remote loading [10]. Here we only briefly introduce several technologies of ⁶⁴Cu radiolabeled liposomes, and discuss their corresponding advantages and disadvantages. Surface functionalized ⁶⁴Cu radiolabeled liposomes are realized by attaching or conjugating different kinds of chelating agents (BAT, DOTA, TETA) to the surface of liposomes [112-122]. This can flexibly realize the application of different nuclides and the alternative of targeting motifs for different disease models. However, several reports have also manifested that ⁶⁴Cu radiolabeled liposomes of surface functionalized chelating agent cause radio stability in serum and in vivo. The predecessors have made a detailed review of this part [10, 34, 123, 124].

2.3.1 Liposomes encapsulated with chelating agents for ⁶⁴Cu PET imaging

Radiolabeling of liposomes can also be achieved within the liposome core to improve the stability of radiolabeling [10]. This type of radiolabeling procedure is relatively complicated, and usually requires pre-synthesis of a radiotracer before incorporation into liposomes. The most widely used intraliposomal radiolabeling method uses ionophores to transport radionuclides through the lipid bilayer to chelate with internally encapsulated chelating agents [125-134]. Peterson et al. innovatively constructed a liposome that uses ionophore 2-hydroxyquinoline (2HQ) to deliver ⁶⁴Cu²⁺ through phospholipids, and successfully encapsulated the chelating agent DOTA inside the liposome [126]. Due to the passive encapsulation of DOTA, it does have the inflexibility of radioactive labeling. Hendriks et al. designed ⁶⁴Cu radiolabeled liposomes using a new chelating agent 4-DEAP-ATSC as a ⁶⁴Cu²⁺ loading and trapping agent [133]. This method can firstly chelate 4-DEAP-ATSC with ⁶⁴Cu externally, and then load into liposomes through the liposome bilayer to achieve stable PET imaging.

In addition, Rosales et al. reported that doxorubicin (DOX), an anticancer drug with metal chelating properties, can be used for radiolabeling of liposomes without the need for additional chelating agents [134]. It has been demonstrated that after ionophore-mediated transport across the lipid bilayer, the hydroxyl and carbonyl groups on the DOX backbone interact with the radionuclide ⁶⁴Cu, which allows multiple liposomes to simultaneously perform ⁶⁴Cu PET imaging and drug delivery. This approach overcomes the binding of liposomes with additional chelating agents, but the extent of radiolabeling allowed by this method is limited by the strength of the interaction between radionuclides and the drugs in the liposomes.

3 Summary and prospects

Less

The ⁶⁴Cu radiolabeled nanomaterial is an effective nanoplatform and has achieved promising results in PET imaging, image-guided drug delivery, and therapeutic diagnosis. Due to its unique advantages, the latest advances in ⁶⁴Cu radiolabeled nanomaterials have greatly promoted the basic understanding of the role of ⁶⁴Cu PET imaging in cancer diagnosis. In this review, we mainly summarized the general strategies and progress of ⁶⁴Cu radiolabeled nanomaterials, including hot-plus-cold precursors strategy ([⁶⁴Cu]Cu clusters), doping nanoparticles ([⁶⁴Cu]CuS, [⁶⁴Cu]CuO nanoparticles and metal doping nanoparticles) and other functionalized radiolabels (chelating agent-based labeling and ionophore-based remote loading), and further analyzed their PET imaging in tumor models. The challenges left by these advancements point us to many future directions and efforts in the design and construction of ⁶⁴Cu radiolabeled nanomaterial probes:

• In vivo stability and effective labeling of radionuclides. Although existing probes can achieve PET imaging of tumor, more accurate PET quantification in lesions is still a challenging problem. Since the PET signal comes from a radionuclide, it is crucial that PET imaging platform possess a stable chelating agent or favorable internal doping strategy. The lack of stability may lead to the destruction of the imaging agent, which means the release of free radionuclide [135]. For example, free ⁶⁴Cu may more easily flow out of tissues and enter the bloodstream, leading to secondary absorption by other organs. In the liver and even tumors, it may be difficult to distinguish the free radionuclide signal from ⁶⁴Cu signal inherent in the probe [136, 137]. In addition, the internal incorporation strategy may cause time-consuming and radioactive labeling effectiveness issues due to the complicated design process [138-140]. In this case, the development of reliable radiolabeled nanomaterials is still one of the important research directions.

• The biosafety of radioactive nanoprobes and the feasibility of clinical transformation. The ⁶⁴Cu radiolabeled probe with high sensitivity and quantitative capacity can realize pathological detection in animals and clinical tissues. However, biosafety is an important indicator in actual biomedical applications [141]. First, the potential risk of radiation damage cannot be ignored. In order to minimize the risk of radiation, it is recommended that the dose of ⁶⁴Cu nuclides meet the window period for radiolabeling and subsequent imaging [11, 12, 139]. In addition, the relatively large size and surface area of nanomaterials may limit their ability to access predetermined goals and affect excretion in vivo [142]. It is feasible to modify the stealth coating on the surface of nanomaterials or rationally design the intelligent biodegradable nanoprobes to further satisfy the future clinical biological application.

• The integration of radioactive nanomaterials and nanomedicine. In addition to PET imaging, it has also been found that the relatively large surface area of nanomaterials can simultaneously load anticancer drugs and radiotracers to achieve the dual functions of diagnosis and therapy [37, 143, 144]. The integrated platform can use PET imaging to accurately monitor drug release in deep tissues. In addition, the Cherenkov radiation of the radionuclide ⁶⁴Cu is used as controllable internal light source to activate the photosensitizers for tumor photodynamic therapy [145]. Therefore, the development of more comprehensive diagnosis and therapy nanomaterials is conducive to image-guided surgical treatment, so as to further meet the actual needs of clinical medicine.

In summary, ⁶⁴Cu radiolabeled nanomaterials have made tremendous progress in radiolabeling strategies and tumor diagnosis. It is expected that more versatile radiolabeled nanomaterials will flourish in theranostics, accelerating the transformation of ⁶⁴Cu radiolabeled nanomaterials from laboratory to clinical practice, and ultimately benefit patients.

Declaration of competing interest

Less

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Acknowledgments

Less

This work was supported by the National Natural Science Foundation of China (Nos. U2067214, 21727817), Beijing municipal education commission-Beijing natural science foundation joint funding project (No. KZ202010005006).

References

Less

[1]

M.F. Ullah, M. Aatif, Cancer Treat. Rev. 35(2009) 193-200.

[2]

S.K. Arya, S. Bhansali, Chem. Rev. 111(2011) 6783-6809.

[3]

M. Gao, F. Yu, C. Lv, J. Choo, L. Chen, Chem. Soc. Rev. 46(2017) 2237-2271.

[4]

A. Razgulin, N. Ma, J. Rao, Chem. Soc. Rev. 40(2011) 4186-4216.

[5]

D. Su, L. Gao, F. Gao, X. Zhang, X. Gao, Chem. Sci. 11(2020) 5614-5629.

[6]

D. Su, X. Chen, Y. Zhang, X. Gao, Trac-Trends Anal. Chem. 133(2020) 116112.

[7]

Y. Xing, J. Zhao, P.S. Conti, K. Chen, Theranostics 4(2014) 290-306.

[8]

K. Heinzmann, L.M. Carter, J.S. Lewis, E.O. Aboagye, Nat. Biomed. Eng. 1(2017) 697-713.

[9]

H.S. Krishnan, L. Ma, N. Vasdev, S.H. Liang, Chem. Eur. J. 23(2017) 15553-15577.

[10]

J. Pellico, P.J. Gawne, R. T.M. d. R, Chem. Soc. Rev. 50(2021) 3355-3423.

[11]

S.R. Cherry, T. Jones, J.S. Karp, et al., J. Nucl. Med. 59(2018) 3-12.

[12]

R.D. Badawi, H. Shi, P. Hu, et al., J. Nucl. Med. 60(2019) 299-303.

[13]

K.V. Vimalnath, A. Rajeswari, K.C. Jagadeesan, et al., J. Radioanal. Nucl. Chem. 294(2012) 43-47.

[14]

R. Chakravarty, S. Chakraborty, A. Dash, Mol. Pharmaceutics 13(2016) 3601-3612.

[15]

L.A. Bass, M. Wang, M.J. Welch, C.J. Anderson, Bioconjugate Chem. 11(2000) 527-532.

[16]

T.J. Wadas, E.H. Wong, G.R. Weisman, C.J. Anderson, Curr. Pharm. Des. 13(2007) 3-16.

[17]

P. Szymanski, T. Fraczek, M. Markowicz, E. Mikiciuk-Olasik, BioMetals 25(2012) 1089-1112.

[18]

M.T. Ma, P.S. Donnelly, Curr. Top. Med. Chem. 11(2011) 500-520.

[19]

S. Li, C.G. England, E.B. Ehlerding, Am. J. Transl. Res. 11(2019) 6007-6015.

[20]

D.W. Bartlett, H. Su, I.J. Hildebrandt, W.A. Weber, M.E. Davis, Proc. Natl. Acad. Sci. U. S. A. 104(2007) 15549-15554.

[21]

K. Chen, X. Sun, G. Niu, et al., Mol. Imaging Biol. 14(2012) 96-105.

[22]

A. Krishnan, V. Adhikarla, E.K. Poku, et al., Blood Adv. 4(2020) 5194-5202.

[23]

Y. Zhang, C. Zhang, C. Xu, et al., Talanta 200(2019) 432-442.

[24]

J. Ge, Q. Zhang, J. Zeng, Z. Gu, M. Gao, Biomaterials 228(2020) 119553.

[25]

N. Khlebtsov, L. Dykman, Chem. Soc. Rev. 40(2011) 1647-1671.

[26]

E. Porret, X. Le Guevel, J.L. Coll, J. Mater. Chem. B 8(2020) 2216-2232.

[27]

J.E. Mortimer, J.R. Bading, J.M. Park, et al., J. Nucl. Med. 59(2018) 38-43.

[28]

S.K. Woo, S.J. Jang, M.J. Seo, et al., J. Nucl. Med. 60(2019) 26-33.

[29]

A.C. Sedgwick, J.T. Brewster, P. Harvey, et al., Chem. Soc. Rev. 49(2020) 2886-2915.

[30]

Q. Fan, K. Cheng, X. Hu, et al., J. Am. Chem. Soc. 136(2014) 15185-15194.

[31]

R. Zhang, Q. Fan, M. Yang, et al., Adv. Mater. 27(2015) 5063-5069.

[32]

T.M. Shaffer, S. Harmsen, E. Khwaja, et al., Nano Lett. 16(2016) 5601-5604.

[33]

S. Shen, D. Jiang, L. Cheng, et al., ACS Nano 11(2017) 9103-9111.

[34]

C. Perez-Medina, A.J.P. Teunissen, E. Kluza, W.J.M. Mulder, R. van der Meel, Adv. Drug Delivery Rev. 154(2020) 123-141.

[35]

Y. Zhao, D. Sultan, L. Detering, et al., Angew. Chem. Int. Ed. 53(2014) 156-159.

[36]

Y. Tao, M. Li, J. Ren, X. Qu, Chem. Soc. Rev. 44(2015) 8636-8663.

[37]

X. Sun, W. Cai, X. Chen, Acc. Chem. Res. 48(2015) 286-294.

[38]

F. Gao, P. Cai, W. Yang, et al., ACS Nano 9(2015) 4976-4986.

[39]

X. Sun, X. Huang, X. Yan, et al., ACS Nano 8(2014) 8438-8446.

[40]

M. Yang, D. Huo, K.D. Gilroy, et al., ChemNanoMat 3(2017) 44-50.

[41]

A.F. Frellsen, A.E. Hansen, R.I. Jolck, et al., ACS Nano 10(2016) 9887-9898.

[42]

Y. Zhao, D. Sultan, L. Detering, H. Luehmann, Y. Liu, Nanoscale 6(2014) 13501-13509.

[43]

A. Niccoli Asabella, G.L. Cascini, C. Altini, et al., BioMed Res. Int. (2014) 7864632014.

[44]

M. Shokeen, C.J. Anderson, Acc. Chem. Res. 42(2009) 832-841.

[45]

G.S. Heo, Y. Zhao, D. Sultan, et al., ACS Appl. Mater. Interfaces 11(2019) 19669-19678.

[46]

X. Zhang, D. Ye, L. Yang, et al., ACS Appl. Nano Mater. 3(2020) 11129-11134.

[47]

M. Zhou, R. Zhang, M. Huang, et al., J. Am. Chem. Soc. 132(2010) 15351-15358.

[48]

M. Zhou, J. Li, S. Liang, et al., ACS Nano 9(2015) 7085-7096.

[49]

Z. Wang, P. Huang, O. Jacobson, et al., ACS Nano 10(2016) 3453-3460.

[50]

X. Zhang, L. Detering, D. Sultan, et al., ACS Nano 15(2021) 1186-1198.

[51]

D. Ye, D. Sultan, X. Zhang, et al., J. Control. Release 283(2018) 143-150.

[52]

D. Ye, X. Zhang, Y. Yue, et al., J. Control. Release 286(2018) 145-153.

[53]

Y. Zhao, L. Detering, D. Sultan, et al., ACS Nano 10(2016) 5959-5970.

[54]

D. Sultan, W. Li, L. Detering, et al., Nanomed. Nanotechnol. Biol. Med. 36(2021) 102416.

[55]

H. Hu, P. Huang, O.J. Weiss, et al., Biomaterials 35(2014) 9868-9876.

[56]

B. Pang, Y. Zhao, H. Luehmann, et al., ACS Nano 10(2016) 3121-3131.

[57]

R. Madru, M. Budassi, H. Benveniste, et al., Cancer Biother. Radiopharm. 33(2018) 213-220.

[58]

Y. Wang, Y. Liu, H. Luehmann, et al., ACS Nano 6(2012) 5880-5888.

[59]

Y. Zhao, B. Pang, L. Detering, et al., Mol. Imaging 17(2018) 1536012118775827.

[60]

H. Xie, B. Goins, A. Bao, Z. Wang, W.T. Phillips, Int. J. Nanomed. 7(2012) 2227-2238.

[61]

M. Nahrendorf, H. Zhang, S. Hembrador, et al., Circulation 117(2008) 379-387.

[62]

J. Xie, K. Chen, J. Huang, et al., Biomaterials 31(2010) 3016-3022.

[63]

H.Y. Lee, Z. Li, K. Chen, et al., J. Nucl. Med. 49(2008) 1371-1379.

[64]

R. Torres Martin de Rosales, R. Tavare, R.L. Paul, et al., Angew. Chem. Int. Ed. 50(2011) 5509-5513.

[65]

X. Yang, H. Hong, J.J. Grailer, et al., Biomaterials 32(2011) 4151-4160.

[66]

Z. Liu, W. Cai, L. He, et al., Nat. Nanotechnol. 2(2007) 47-52.

[67]

S. Shi, C. Xu, K. Yang, et al., Angew. Chem. Int. Ed. 56(2017) 2889-2892.

[68]

P. Cai, D. Su, W. Yang, et al., ACS Appl. Bio Mater. 3(2019) 611-621.

[69]

L. Cheng, A. Kamkaew, H. Sun, et al., ACS Nano 10(2016) 7721-7730.

[70]

L. Feng, L. Cheng, Z. Dong, et al., ACS Nano 11(2017) 927-937.

[71]

B. Yu, H. Wei, Q. He, et al., Angew. Chem. Int. Ed. 57(2018) 218-222.

[72]

D. Luo, S. Goel, H.J. Liu, et al., ACS Nano 11(2017) 12482-12491.

[73]

F. Zhang, Q. Ni, O. Jacobson, et al., Angew. Chem. Int. Ed. 57(2018) 7066-7070.

[74]

M.A. Rajora, L. Ding, M. Valic, et al., Chem. Sci. 8(2017) 5371-5384.

[75]

Z. He, H. Jia, M. Zheng, et al., ACS Appl. Bio Mater. 4(2021) 5707-5716.

[76]

J.L.J. Dearling, A.B. Packard, J. Control. Release 261(2017) 23-30.

[77]

W.F. Lai, W.T. Wong, A.L. Rogach, Adv. Mater. 32(2020) 1906872.

[78]

P.S. Patrick, L.K. Bogart, T.J. Macdonald, et al., Chem. Sci. 10(2019) 2592-2597.

[79]

K. Yang, L. Zhu, L. Nie, et al., Theranostics 4(2014) 134-141.

[80]

Z. Zha, S. Wang, S. Zhang, et al., Nanoscale 5(2013) 3216-3219.

[81]

Z. Xiao, Nanomedicine 9(2014) 373-375.

[82]

A. Riedinger, T. Avellini, A. Curcio, et al., J. Am. Chem. Soc. 137(2015) 15145-15151.

[83]

P.K. Jain, I.H. El-Sayed, M.A. El-Sayed, Nano Today 2(2007) 18-29.

[84]

J. Xie, L. Gong, S. Zhu, et al., Adv. Mater. 31(2019) 1802244.

[85]

Y. Zhang, X. Chen, Q. Yuan, et al., Chem. Sci. 12(2021) 14855-14862.

[86]

X. Chen, Y. Zhang, Q. Yuan, et al., J. Mater. Chem. B 9(2021) 6614-6622.

[87]

M. Nahrendorf, E. Keliher, B. Marinelli, et al., Proc. Natl. Acad. Sci. U. S. A. 107(2010) 7910-7915.

[88]

Y. Wang, C. Xu, Y. Chang, et al., ACS Appl. Mater. Interfaces 9(2017) 28959-28966.

[89]

R.M. Wong, D.A. Gilbert, K. Liu, A.Y. Louie, ACS Nano 6(2012) 3461-3467.

[90]

Y. Hu, S. Huang, X. Zhao, L. Chang, Z. Chen, Chem. Eng. J. 421(2021) 129744.

[91]

C.M. Cobley, L. Au, J. Chen, Y. Xia, Expert Opin, Drug Deliv. 7(2010) 577-587.

[92]

R.A. Davis, D.A. Rippner, S.H. Hausner, et al., Environ. Sci. Technol. 51(2017) 12537-12546.

[93]

H. Hong, T. Gao, W. Cai, Nano Today 4(2009) 252-261.

[94]

Z. Liu, S. Tabakman, K. Welsher, H. Dai, Nano Res. 2(2009) 85-120.

[95]

S. Beg, M. Rizwan, A.M. Sheikh, et al., J. Pharm. Pharmacol. 63(2011) 141-163.

[96]

H. Wang, S.T. Yang, A. Cao, Y. Liu, Acc. Chem. Res. 46(2013) 750-760.

[97]

H. Hong, K. Yang, Y. Zhang, et al., ACS Nano 6(2012) 2361-2370.

[98]

X. Huang, F. Zhang, L. Zhu, et al., ACS Nano 7(2013) 5684-5693.

[99]

N. Licciardello, S. Hunoldt, R. Bergmann, et al., Nanoscale 10(2018) 9880-9891.

[100]

Y. Peng, D. Yang, W. Lu, et al., Acta Biomater 61(2017) 193-203.

[101]

G. Biagiotti, F. Pisaneschi, S.T. Gammon, F, et al., J. Mater. Chem. B 7(2019) 2678-2687.

[102]

B.T. Cisneros, J.J. Law, M.L. Matson, et al., Nanomedicine 9(2014) 2499-2509.

[103]

J. Xu, S. Yu, X. Wang, et al., ACS Nano 13(2019) 10242-10260.

[104]

L. Huang, S. Asghar, T. Zhu, et al., Expert Opin. Drug Delivery 18(2021) 1473-1500.

[105]

S. Kumar, D. Jiang, B. Sun, et al., Adv. NanoBiomed Res. 1(2021) 2000013.

[106]

B. Liu, G. Qiao, Y. Han, et al., Acta Biomater 117(2020) 361-373.

[107]

W. Fan, B. Yung, P. Huang, X. Chen, Chem. Rev. 117(2017) 13566-13638.

[108]

W. Yu, J. Huang, M. Lin, et al., Anal. Chem. 93(2021) 4647-4656.

[109]

G. Yang, S.Z.F. Phua, W.Q. Lim, et al., Adv. Mater. 31(2019) 1901513.

[110]

E. Chang, J. Bu, L. Ding, et al., J. Nanobiotechnol. 19(2021) 154.

[111]

T.W. Liu, T.D. MacDonald, J. Shi, B.C. Wilson, G. Zheng, Angew. Chem. Int. Ed. 51(2012) 13128-13131.

[112]

J.W. Seo, H. Zhang, D.L. Kukis, C.F. Meares, K.W. Ferrara, Bioconjugate Chem. 19(2008) 2577-2584.

[113]

E.E. Paoli, D.E. Kruse, J.W. Seo, et al., J. Control. Release 143(2010) 13-22.

[114]

C.B. Rygh, S. Qin, J.W. Seo, et al., Clin. Cancer Res. 17(2011) 550-559.

[115]

C.M. Kang, H.J. Koo, S. Lee, et al., Nucl. Med. Biol. 40(2013) 1018-1024.

[116]

L.M. Mahakian, D.G. Farwell, H. Zhang, et al., Mol. Imaging Biol. 16(2014) 284-292.

[117]

S.G. Lee, K. Gangangari, T.M. Kalidindi, et al., Nucl. Med. Biol. 43(2016) 781-787.

[118]

Y. Du, X. Liang, Y. Li, et al., Mol. Pharmaceutics 14(2017) 3978-3986.

[119]

A.I. Jensen, G.W. Severin, A.E. Hansen, et al., J. Control. Release 269(2018) 100-109.

[120]

A.W. Wong, E. Ormsby, H. Zhang, et al., Am. J. Nucl. Med. Mol. Imaging 3(2013) 32-43.

[121]

J.W. Seo, L.M. Mahakian, A. Kheirolomoom, et al., Bioconjugate Chem. 21(2010) 1206-1215.

[122]

J.W. Seo, S. Qin, L.M. Mahakian, et al., J. Control. Release 151(2011) 28-34.

[123]

M. Jaymand, Y. Davatgaran Taghipour, A. Rezaei, et al., Coord. Chem. Rev. 440(2021) 213974.

[124]

Y. Liu, M.J. Welch, Bioconjugate Chem. 23(2012) 671-682.

[125]

A.E. Hansen, A.L. Petersen, J.R. Henriksen, et al., ACS Nano 9(2015) 6985-6995.

[126]

A.L. Petersen, T. Binderup, P. Rasmussen, et al., Biomaterials 32(2011) 2334-2341.

[127]

L.W. Locke, M.W. Mayo, A.D. Yoo, M.B. Williams, S.S. Berr, Biomaterials 33(2012) 7785-7793.

[128]

J.R. Henriksen, A.L. Petersen, A.E. Hansen, et al., ACS Appl. Mater. Interfaces 7(2015) 22796-22806.

[129]

B. Borresen, J.R. Henriksen, G. Clergeaud, et al., ACS Nano 12(2018) 11386-11398.

[130]

H. Lee, J. Zheng, D. Gaddy, et al., Nanomedicine 11(2015) 155-165.

[131]

S.J. Blocker, K.A. Douglas, L.A. Polin, et al., Theranostics 7(2017) 4229-4239.

[132]

H. Lee, A.F. Shields, B.A. Siegel, et al., Clin. Cancer Res. 23(2017) 4190-4202.

[133]

H. Lee, D. Gaddy, M. Ventura, et al., Theranostics 8(2018) 2300-2312.

[134]

S. Edmonds, A. Volpe, H. Shmeeda, et al., ACS Nano 10(2016) 10294-10307.

[135]

M.D. Majmudar, J. Yoo, E.J. Keliher, et al., Circ. Res. 112(2013) 755-761.

[136]

M.L. Senders, A.E. Meerwaldt, M.M.T. van Leent, et al., Nat. Nanotechnol. 15(2020) 398-405.

[137]

J. Llop, P. Jiang, M. Marradi, et al., J. Mater. Chem. B 3(2015) 6293-6300.

[138]

M. Lameijer, T. Binderup, M.M.T. van Leent, et al., Nat. Biomed. Eng. 2(2018) 279-292.

[139]

J.L.J. Dearling, A.B. Packard, J. Control. Release 261(2017) 23-30.

[140]

D.L. Bailey, K.P. Willowson, Eur. J. Nucl. Med. Mol. Imaging 41(2014) S17-S25.

[141]

A. Hosny, C. Parmar, J. Quackenbush, L.H. Schwartz, H.J.W.L. Aerts, Nat. Rev. Cancer 18(2018) 500-510.

[142]

G. Wang, J.C. Ye, K. Mueller, J.A. Fessler, IEEE Trans. Med. Imaging 37(2018) 1289-1296.

[143]

P. Zou, H. Chen, H.J. Paholak, D. Sun, Mol. Pharmaceutics 10(2013) 4185-4194.

[144]

L. Wang, L. Yan, J. Liu, C. Chen, Y. Zhao, Anal. Chem. 90(2018) 589-614.

[145]

J. Guo, K. Feng, W. Wu, et al., Angew. Chem. Int. Ed. 60(2021) 21884-21889.

Appendix

Less

Year 2022 volume 33 Issue 7

PDF

Cite this Article

BibTeX

Article Info

doi: 10.1016/j.cclet.2022.02.070

Receive Date：2021-12-01
Online Date：2025-12-19
Published：2022-07-15

Article Data

Affiliations

History

Received：2021-12-01
Revised：2022-02-25
Accepted：2022-02-25

Affiliations

Department of Chemistry and Biology, Faculty of Environment and Life, Beijing University of Technology, Beijing 100124, China

References

Share

https://castjournals.cast.org.cn/joweb/ccl/EN/10.1016/j.cclet.2022.02.070

Share to

Scan QR to access full text

Cite this article

BibTeX

Citations

表12种不同金属材料的力学参数

科 Family	属数 Number of genus	种数 Number of species	占总种数比例 Percentage of total species (%)	属 Genus	种数 Number of species	占总种数比例 Percentage of total species (%)
鹅膏菌科Amanitaceae	2	11	5.26	鹅膏菌属 Amanita	10	4.78
小菇科 Mycenaceae	2	12	5.74	丝盖伞属 Inocybe	5	2.39
多孔菌科 Polyporaceae	8	14	6.70	蜡蘑属 Laccaria	5	2.39
红菇科 Russulaceae	3	23	11.00	小皮伞属 Marasmius	6	2.87
				小菇属 Mycena	11	5.26
				光柄菇属 Pluteus	5	2.39
				红菇属 Russula	17	8.13
				栓菌属 Trametes	5	2.39

关闭全屏

BibTeX
EndNote
RefWorks
TxT

Fig. 1 Schematic of ⁶⁴Cu radiolabeling strategies.

Fig. 2 (A) Schematic diagram of ⁶⁴Cu radiolabeled Cu clusters. (B) In vivo PET imaging of [⁶⁴Cu]Cu_NC@BSA-LHRH on orthotopic A549 lung tumor bearing mice. Reproduced with permission [38]. Copyright 2015, American Chemical Society. (C) In vivo PET imaging of ⁶⁴Cu-CuNCs-FC131 in a 4T1 mouse TNBC model and CXCR4^high PDX model and autoradiography of human TNBC tissues. Reproduced with permission [45]. Copyright 2019, American Chemical Society.

Fig. 3 (A) Schematic of ⁶⁴Cu radiolabeled CuS and CuO nanomaterials. (B) In vivo PET/PA imaging and PTT of ⁶⁴CuS-Fn NCs. Reproduced with permission [49]. Copyright 2016, American Chemical Society. (C) In vivo PET imaging and biodistribution of ⁶⁴Cu-Cu@CuOx-ECL1i in wild-type littermate, 7–9 weeks old KPPC mice. Reproduced with permission [50]. Copyright 2021, American Chemical Society.

Fig. 4 (A) Schematic of ⁶⁴Cu radiolabeled Au nanomaterials. (B) Representative PET/CT images in tumor-bearing mice of ⁶⁴CuAuNPs. Reproduced with permission [35]. Copyright 2013, Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim. (C) In vivo PET/CT imaging of ⁶⁴CuAuNCs-AMD3100 in 4T1 tumor-bearing mice at 1 and 4 weeks after tumor implant, T: tumor, M: metastasis. Reproduced with permission [53]. Copyright 2016, American Chemical Society. (D) In vivo PET imaging and biodistribution of RGD-[⁶⁴Cu]AuNR808 in U87MG tumor-bearing mice, white arrows: tumor. Reproduced with permission [39]. Copyright 2014, American Chemical Society.

Fig. 5 (A) Schematic representation of ⁶⁴Cu-chelator radiolabeled Au nanomaterials. (B) TEMimage, in vivo PET/CT imaging and autoradiography about intratumoral accumulation of 30 nm-sized ⁶⁴Cu-DOTA-PEG-AuNCs in EMT-6 breast cancer mouse model. Reproduced with permission [58]. Copyright 2012, SAGE publications. (C) PET/CT images of ⁶⁴Cu-AuNCs-PEG-MSH in melanocortin 1 receptor upregulated B16/F10 melanoma tumor-bearing mice. Reproduced with permission [59]. Copyright 2018, SAGE Publications.

Fig. 6 (A) Schematic representation of ⁶⁴Cu-chelating agent radiolabeled ironoxide nanomaterials. (B) in vivo PET/NIRF/MRI trimodality imaging in a subcutaneous U87MG tumor-bearing mice. Reproduced with permission [62]. Copyright 2010, Elsevier. (C) PET/CT images of ⁶⁴Cu-labeled and cRGD-conjugated SPIO nanocarriers in a U87MG tumor-bearing mouse. Reproduced with permission [65], Copyright 2011, Elsevier.

Fig. 7 (A) Schematic of construction of ⁶⁴Cu@LCI-apt and ⁶⁴Cu@LCI-ctrl and their applications of PET/CT imaging on orthotopic A549 lung tumor mice. Reproduced with permission [68]. Copyright 2020, American Chemical Society. (B) Schematic of Dox-CuPoP and its applications of optical/PET imaging and chemophototherapy on orthotopic 4T1 mammary tumors mice. Reproduced with permission [72]. Copyright 2017, American Chemical Society.

Fig. 8 (A) Design of GSH-sensitive CPT-ss-HPPH and PET images of CPT-ss-HPPH NPs and GSH-insensitive HPPH NPs in HCT116 tumor-bearing mice. Reproduced with permission [73]. Copyright 2017, Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim. (B) Schematic Diagram of Trp2/⁶⁴Cu@PPa-PEGm NPs for PET imaging tracking and dendritic cell-based immunotherapy. Reproduced with permission [75]. Copyright 2021, American Chemical Society, .

Articles: Latest Articles; Most Read; Collections

Updates: Events; News; Multimedia

About: About Us

Contact

No. 86 Xueyuan South Road, Haidian District, Beijing

100081

010-62199257

qkjq@cast.org.cn

Copyright © 2025 China Association for Science and Technology. All rights reserved. For all open access content, the relevant licensing terms apply.
Sponsored by the Office of the Leading Group for Cybersecurity and Informatization of CAST, and supported by Science and Technology Review Publishing House